<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00634959</url>
  </required_header>
  <id_info>
    <org_study_id>A4001015</org_study_id>
    <nct_id>NCT00634959</nct_id>
  </id_info>
  <brief_title>Effects Of Food And Dose Regimen On The Antiviral Effects Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus</brief_title>
  <official_title>An Investigation Into The Effects Of Food And Dose Regimen On Viral Load Response In HIV Infected Patients On Short-Term Monotherapy With UK-427,857 (Maraviroc)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ViiV Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the effects of food and dose regimen on the antiviral effects of Maraviroc
      (UK-427,857) in patients with human immunodeficiency virus (HIV)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">December 2003</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in viral load</measure>
    <time_frame>Day 11</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>UK-427,857 pharmacokinetics</measure>
    <time_frame>Days 1-11</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physical examination</measure>
    <time_frame>Days 1, 11, 40</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-lead ECG</measure>
    <time_frame>Days 1-11 and Day 40</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship of change in viral load (baseline to Day 11) versus mean receptor saturation (Day 10)</measure>
    <time_frame>Days 1-11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time course of viral load from baseline to follow-up</measure>
    <time_frame>Days 1-13 and Days 15, 19, 22, 25, 40</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CCR5 receptor saturation</measure>
    <time_frame>Days 1, 5, 10, 11, 13, 15, 19, 40</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Days 1-40</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship of change in viral load (baseline to Day 11) versus baseline susceptibility (IC50 and IC90)</measure>
    <time_frame>Days 1-11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory safety</measure>
    <time_frame>Days 1, 3, 7, 11, 15, 40</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship of change in viral load (baseline to Day 11) versus average and trough plasma concentrations (Day 10)</measure>
    <time_frame>Days 1-11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Supine/standing blood pressure and pulse rate</measure>
    <time_frame>Days 1-11 and Day 40</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to rebound of viral load</measure>
    <time_frame>Days 1-13 and Days 15, 19, 22, 25, 40</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maraviroc (UK-427,857)</intervention_name>
    <description>150 mg oral tablet twice daily while fasted on Days 1-9 and on Day 10 (morning dose only)</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Celsentri, Selzentry</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maraviroc (UK-427,857)</intervention_name>
    <description>100 mg oral tablet once daily while fasted on Days 1-10</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Celsentri, Selzentry</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maraviroc (UK-427,857)</intervention_name>
    <description>300 mg oral tablet once daily while fasted on Days 1-10</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Celsentri, Selzentry</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maraviroc (UK-427,857)</intervention_name>
    <description>150 mg oral tablet twice daily with food on Days 1-9 and on Day 10 (morning dose only)</description>
    <arm_group_label>4</arm_group_label>
    <other_name>Celsentri, Selzentry</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo oral tablet on Days 1-10 (fed and fasted)</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Asymptomatic HIV-1 infected male and female patients

          -  Weight between 50 and 100kg and within the permitted range for their height

          -  Patients with virus that targets CCR5 receptor

        Exclusion Criteria:

          -  Patients with a CD4 count &lt;250 cells/mm3 or HIV viral load &lt;5000 copies/mL

          -  Patients whose HIV infection has been diagnosed less than 3 months prior to screening,
             or for who there is evidence of recent seroconversion

          -  Patients with acquired immunodeficiency syndrome (AIDS) or a previous AIDS diagnosis

          -  Patients who are taking or have taken antiretroviral drugs in the eight weeks prior to
             the study screening visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-2050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Koeln</city>
        <zip>50931</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SW10 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4001015&amp;StudyName=Effects%20Of%20Food%20And%20Dose%20Regimen%20On%20The%20Antiviral%20Effects%20Of%20Maraviroc%20%28UK-427%2C857%29%20In%20Patients%20With%20Human%20Immunodeficiency%20Virus</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2008</study_first_submitted>
  <study_first_submitted_qc>March 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2008</study_first_posted>
  <last_update_submitted>November 9, 2010</last_update_submitted>
  <last_update_submitted_qc>November 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>HIV Infections</keyword>
  <keyword>Treatment Na√Øve</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maraviroc</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

